We are focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.

Our technology

The unique potential of Radiopharmaceuticals in treating oncological diseases.

Learn more

Our pipeline

The unique potential of being First to Market or Best in Class.

Learn more

Our team

We have a unique commitment to improve patients’ hope in fighting cancer.

Learn more

Information for investors

Stock price, Company governance & updates from our multiple development programs.

Learn more

Latest news

ASX Releases

May 29, 2023

FDA Pre-IND Meeting Supports an IND Application for RAD101

Read moreRead more

ASX Releases

May 9, 2023

RAD Receives FDA Orphan Drug Designation for Trivehexin (RAD301) in Pancreatic Cancer

Read moreRead more

Media Coverage

May 2, 2023

Positive new publication for RAD301 platform

Read moreRead more